吉西他滨联合顺铂治疗晚期非小细胞肺癌临床分析  

Clinical study of gemcitabine plus cisplatin in treatment of advanced non-small cell lung cancer

作　　者：于晶琳[1] 赵玉亮[1] 林蓉燕[1] 孙明霞[1] 王晓云[1] 

机构地区：[1]北京大学第一医院肿瘤化疗科,北京100034

出　　处：《中国肿瘤临床与康复》2008年第5期447-449,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的评估吉西他滨联合顺铂治疗晚期非小细胞肺癌的近期疗效和安全性。方法对33例晚期非小细胞肺癌患者采用吉西他滨1000 mg/m2,静滴,第1、8天;顺铂35 mg/m2,静滴,第1、2天。3周为1个周期,2个周期后进行一次疗效评价。结果33例患者中完全缓解(CR)0例,部分缓解(PR)14例,稳定(SD)14例,进展(PD)5例,总有效率(CR+PR)为42.4%。初治优于复治(54.2%对11.1%,P=0.030)。中位疾病进展时间(TTP)5.2个月。本方案的主要毒副作用是Ⅲ/Ⅳ度血小板减少和胃肠道反应。结论吉西他滨联合顺铂3周方案治疗晚期非小细胞肺癌患者具有良好的疗效和较低的毒副作用。Objective To evaluate the efficacy and safety of gemcitabine （GEM） plus cisplatin （DDP） in treatment of advanced non-small cell lung cancer. Methods Thirty-three cases of advanced non- small cell lung cancer were treated with GEM （1000mg/m^2, day 1 ,day 8） iv gtt and DDP（35mg/m^2 ,day 1, day 2） iv gtt. Three weeks constituted one cycle. After 2 cycles, the overall response rate and side effects were evaluated. Results Fourteen cases （ 42.4% ） showed partial response （ PR ）, while 14 cases （42.4%） had stable disease（SD） and 5 cases （ 15. 2% ） showed progress of disease （PD） ;the overall response rate was 42.4%. The response rate was higher in previously untreated cases than in treated cases （54. 2% vs 11.1%, P =0. 030）. The median time to progression（TTP） was 5. 2 months. Main side effects were grade 3/4 thrombocytopenia and gastrointestinal tract toxicity. Conclusion GEM plus DDP is effective and safe in the treatment of advanced non-small cell lung cancer.

关 键 词：肺肿瘤/化学疗法 吉西他滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]